Nuclear factor-κB is involved in the protocadherin-10-mediated pro-apoptotic effect in multiple myeloma

Li,Zhen; Yang,Zesong; Peng,Xi; Li,Ying; Liu,Qiong; Chen,Jianbin

doi:10.3892/mmr.2014.2285

Nuclear factor-κB is involved in the protocadherin-10-mediated pro-apoptotic effect in multiple myeloma

Authors:
- Zhen Li
- Zesong Yang
- Xi Peng
- Ying Li
- Qiong Liu
- Jianbin Chen
View Affiliations

Affiliations: Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China, Department of Hematology, Chongqing Three Gorges Central Hospital, Chongqing, P.R. China, Department of Emergency, The First Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China
Published online on: May 29, 2014 https://doi.org/10.3892/mmr.2014.2285
Pages: 832-838

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The gene encoding protocadherin-10 (PCDH10), a member of the cadherin superfamily, has been recently identified as a tumor suppressor gene (TSG). PCDH10 plays important roles in the apoptosis of tumor cells in some cancer types. However, the exact role of PCDH10 in multiple myeloma (MM) is largely unknown. Increasing evidence has suggested that the activation of nuclear factor-κB (NF-κB) is crucial for apoptosis in myeloma cells. In this study, we investigated the pro-apoptotic effect of PCDH10 on myeloma cells and whether this effect may involve inhibition of the NF-κB pathway. We report here, for the first time to the best of our knowledge, that PCDH10 markedly induces apoptosis of myeloma cells, accompanied by an increase in activated caspase-3 and poly-ADP‑ribose polymerase (PARP) levels, and inhibited expression of anti‑apoptotic proteins. We also demonstrate that PCDH10 inhibits the activation of NF-κB, by inhibiting the expression of the inhibitor of nuclear factor-κB (IκB) kinase subunits (IKKs) and the phosphorylation of IκBα. Moreover, the constitutive NF-κB DNA-binding activity and the expression of the NF-κB‑regulated proteins cyclooxygenase-2 (COX-2), vascular endothelial growth factor (VEGF) and intercellular adhesion molecule 1 (ICAM-1) were inhibited by PCDH10 in MM cells. These results suggest that PCDH10 induces myeloma cell apoptosis, probably by inhibiting the NF-κB pathway.

View Figures

View References

1	Di Bernardo A, Macor P, Guarnotta C, et al: Humoral immunotherapy of multiple myeloma: perspectives and perplexities. Exp Opin Biol Ther. 10:863–873. 2010.PubMed/NCBI
2	Palumbo A and Mina R: Management of older adults with multiple myeloma. Blood Rev. 27:133–142. 2013. View Article : Google Scholar : PubMed/NCBI
3	Dalton WS: Drug resistance and drug development in multiple myeloma. Semin Oncol. 29:21–25. 2002. View Article : Google Scholar : PubMed/NCBI
4	Bommert K, Bargou RC and Stuhmer T: Signalling and survival pathways in multiple myeloma. Eur J Cancer. 42:1574–1580. 2006. View Article : Google Scholar : PubMed/NCBI
5	Ni H, Ergin M, Huang Q, et al: Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol. 115:279–286. 2001. View Article : Google Scholar : PubMed/NCBI
6	Wolverton T and Lalande M: Identification and characterization of three members of a novel subclass of protocadherins. Genomics. 76:66–72. 2001. View Article : Google Scholar : PubMed/NCBI
7	Bertrand KC, Mack SC, Northcott PA, et al: PCDH10 is a candidate tumour suppressor gene in medulloblastoma. Childs Nerv Syst. 27:1243–1249. 2011. View Article : Google Scholar : PubMed/NCBI
8	Li Y, Yang ZS, Song JJ, Liu Q and Chen JB: Protocadherin-10 is involved in angiogenesis and methylation correlated with multiple myeloma. Int J Mol Med. 29:704–710. 2012.PubMed/NCBI
9	Li Z, Li W, Xie J, et al: Epigenetic inactivation of PCDH10 in human prostate cancer cell lines. Cell Biol Int. 35:671–676. 2011. View Article : Google Scholar : PubMed/NCBI
10	Li Z, Xie J, Li W, et al: Identification and characterization of human PCDH10 gene promoter. Gene. 475:49–56. 2011. View Article : Google Scholar : PubMed/NCBI
11	Ma JG, He ZK, Ma JH, Li WP and Sun G: Downregulation of protocadherin-10 expression correlates with malignant behaviour and poor prognosis in human bladder cancer. J Int Med Res. 41:38–47. 2013. View Article : Google Scholar : PubMed/NCBI
12	Narayan G, Scotto L, Neelakantan V, et al: Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer. Genes Chromosomes Cancer. 48:983–992. 2009. View Article : Google Scholar : PubMed/NCBI
13	Wang KH, Liu HW, Lin SR, Ding DC and Chu TY: Field methylation silencing of the protocadherin 10 gene in cervical carcinogenesis as a potential specific diagnostic test from cervical scrapings. Cancer Sci. 100:2175–2180. 2009. View Article : Google Scholar : PubMed/NCBI
14	Ying J, Gao Z, Li H, et al: Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies. Br J Haematol. 136:829–832. 2007. View Article : Google Scholar : PubMed/NCBI
15	Ying J, Li H, Seng TJ, et al: Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene. 25:1070–1080. 2006. View Article : Google Scholar
16	Yu B, Yang H, Zhang C, et al: High-resolution melting analysis of PCDH10 methylation levels in gastric, colorectal and pancreatic cancers. Neoplasma. 57:247–252. 2010. View Article : Google Scholar : PubMed/NCBI
17	Yu J, Cheng YY, Tao Q, et al: Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology. 136:640–651.e1. 2009. View Article : Google Scholar : PubMed/NCBI
18	Moreaux J, Legouffe E, Jourdan E, et al: BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. 103:3148–3157. 2004. View Article : Google Scholar : PubMed/NCBI
19	Tai YT, Li XF, Breitkreutz I, et al: Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 66:6675–6682. 2006. View Article : Google Scholar : PubMed/NCBI
20	Aggarwal BB: Nuclear factor-kappaB: the enemy within. Cancer Cell. 6:203–208. 2004.PubMed/NCBI
21	Bharti AC, Shishodia S, Reuben JM, et al: Nuclear factor-kappaB and STAT3 are constitutively active in CD138⁺ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood. 103:3175–3184. 2004.PubMed/NCBI
22	Hideshima T, Chauhan D, Richardson P, et al: NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 277:16639–16647. 2002. View Article : Google Scholar : PubMed/NCBI
23	Li ZW, Chen H, Campbell RA, Bonavida B and Berenson JR: NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol. 15:391–399. 2008. View Article : Google Scholar : PubMed/NCBI
24	Hu Y, Sun CY, Huang J, Hong L, Zhang L and Chu ZB: Antimyeloma effects of resveratrol through inhibition of angiogenesis. Chin Med J. 120:1672–1677. 2007.PubMed/NCBI
25	Sun CY, Hu Y, Guo T, et al: Resveratrol as a novel agent for treatment of multiple myeloma with matrix metalloproteinase inhibitory activity. Acta Pharmacol Sin. 27:1447–1452. 2006. View Article : Google Scholar : PubMed/NCBI
26	Sun C, Hu Y, Liu X, et al: Resveratrol downregulates the constitutional activation of nuclear factor-kappaB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genet Cytogenet. 165:9–19. 2006. View Article : Google Scholar
27	Fernandes-Alnemri T, Litwack G and Alnemri ES: CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem. 269:30761–30764. 1994.PubMed/NCBI
28	Deveraux QL and Reed JC: IAP family proteins - suppressors of apoptosis. Genes Dev. 13:239–252. 1999. View Article : Google Scholar : PubMed/NCBI
29	Gross A, McDonnell JM and Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13:1899–1911. 1999. View Article : Google Scholar : PubMed/NCBI
30	Pahl HL: Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 18:6853–6866. 1999. View Article : Google Scholar : PubMed/NCBI
31	Shimizu H, Mitomo K, Watanabe T, Okamoto S and Yamamoto K: Involvement of a NF-kappa B-like transcription factor in the activation of the interleukin-6 gene by inflammatory lymphokines. Mol Cell Biol. 10:561–568. 1990.PubMed/NCBI
32	Shishodia S and Aggarwal BB: Nuclear factor-kappaB activation: a question of life or death. J Biochem Mol Biol. 35:28–40. 2002. View Article : Google Scholar : PubMed/NCBI
33	Zandi E, Rothwarf DM, Delhase M, Hayakawa M and Karin M: The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell. 91:243–252. 1997. View Article : Google Scholar : PubMed/NCBI